These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 20920848

  • 1. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
    Adeboyeku D, Jones AL, Hodson ME.
    J Cyst Fibros; 2011 Jan; 10(1):25-30. PubMed ID: 20920848
    [Abstract] [Full Text] [Related]

  • 2. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
    Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A, TOPIC Study Group.
    Lancet; 2011 Jan; 365(9459):573-8. PubMed ID: 15708100
    [Abstract] [Full Text] [Related]

  • 3. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T.
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [Abstract] [Full Text] [Related]

  • 4. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M, Nazareth D, Walshaw M.
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E, Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient.
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [Abstract] [Full Text] [Related]

  • 6. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
    Ratjen F, Munck A, Kho P, Angyalosi G, ELITE Study Group.
    Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F, Trivier D, Vic P, Ategbo S, Turck D, Husson MO.
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL.
    N Engl J Med; 1999 Jan 07; 340(1):23-30. PubMed ID: 9878641
    [Abstract] [Full Text] [Related]

  • 12. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Blumer JL, Saiman L, Konstan MW, Melnick D.
    Chest; 2005 Oct 07; 128(4):2336-46. PubMed ID: 16236892
    [Abstract] [Full Text] [Related]

  • 13. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
    Prescott WA, Nagel JL.
    Pharmacotherapy; 2010 Jan 07; 30(1):95-108. PubMed ID: 20030477
    [Abstract] [Full Text] [Related]

  • 14. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR, Bhatt J.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD002009. PubMed ID: 22336782
    [Abstract] [Full Text] [Related]

  • 15. [Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis].
    Prévotat A, Leroy S, Perez T, Wallet F, Wallaert B.
    Rev Mal Respir; 2010 May 15; 27(5):449-56. PubMed ID: 20569877
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J.
    J Cyst Fibros; 2007 Apr 15; 6(2):125-30. PubMed ID: 16829216
    [Abstract] [Full Text] [Related]

  • 17. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
    Mulheran M, Hyman-Taylor P, Tan KH, Lewis S, Stableforth D, Knox A, Smyth A.
    Antimicrob Agents Chemother; 2006 Jul 15; 50(7):2293-9. PubMed ID: 16801404
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CM, Spigarelli MG.
    Pediatr Pulmonol; 2013 Nov 15; 48(11):1047-61. PubMed ID: 24000183
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.